BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines.
“We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage her exceptional experience in immuno-oncology” said Solomon Langermann, PhD, NextCure’s chief scientific officer. “Lisa has an incredible record of leadership and research advancements in cancer immunotherapy, and her expertise in this field will be indispensable as we broaden and advance our product pipeline.”
Dr. Coussens received her PhD from the University of California, Los Angeles, and carried out her post-doctoral work at the University of California, San Francisco. With over 20 years of experience in cancer research, she is currently Professor and Chairwoman of the Cell, Development & Cancer Biology Department, holds the Hildegard Lamfrom Endowed Chair in Basic Science, and is Associate Director for Basic Research in the Knight Cancer Institute at the Oregon Health & Science University in Portland, OR. She is the recipient of multiple prestigious awards in recognition of her contributions to scientific research, including being an elected fellow of the American Association for the Advancement of Science, and a fellow of the American Association for Cancer Research, and will be inducted as a Fellow of the Academy of Immuno-Oncology at the Society for Immunotherapy of Cancer annual meeting in November of this year. In 2022 she was elected to serve as the President of the American Association for Cancer Research. Dr. Coussens’ research focuses on elucidating the role of immune cells in regulating solid tumor development, identifying mechanisms by which immune mechanisms are co-opted to promote cancer development, and in understanding responses to cytotoxic and immune-based therapies. Her research has identified multiple immune-modulatory pathways that are being actively investigated as therapeutic targets for translation to the clinic.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com
Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
